Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06503731
PHASE2

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Sponsor: argenx

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the safety, tolerability, and efficacy of efgartigimod PH20 SC given by a prefilled syringe in participants with Antibody-Mediated Rejection (AMR) after kidney transplantation. After a screening period of up to 6 weeks, eligible participants will be randomized in a 1:1:1 ratio. The study drug will be administered subcutaneously while patients remain on their standard background immunosuppression therapy (tacrolimus, mycophenolate mofetil, steroids) during the treatment period (48 weeks). At the end of the treatment period, the participants will enter an observational/follow-up period (approximately 24 weeks). The participants will be in the study for up to 78 weeks.

Official title: A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2024-08-30

Completion Date

2027-09

Last Updated

2026-03-18

Healthy Volunteers

No

Interventions

COMBINATION_PRODUCT

Efgartigimod PH20 SC - prefilled syringe

Subcutaneous efgartigimod PH20 SC given by prefilled syringe

OTHER

Placebo PH20 SC - prefilled syringe

Subcutaneous placebo PH20 SC given by prefilled syringe

Locations (23)

University of Alabama at Birmingham (UAB) Hospital

Birmingham, Alabama, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

University of Chicago Medical Center

Chicago, Illinois, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

Duke University Hospital

Durham, North Carolina, United States

The Ohio State University Wexner Medical Center

Columbus, Ohio, United States

Virginia Commonwealth University (VCU) Medical Center Hume-Lee Transplant Center

Richmond, Virginia, United States

University of Washington Medical Center

Seattle, Washington, United States

Allgemeines Krankenhaus der Stadt Wien (AKH Wien) - Medizinischer Universitätscampus

Vienna, Austria

Universitair Ziekenhuis (UZ) Gent

Ghent, Belgium

Universitair Ziekenhuis Leuven (UZ Leuven) - Campus Gasthuisberg

Leuven, Belgium

London Health Sciences Centre

London, Canada

Institut klinicke a experimentalni mediciny (IKEM)

Prague, Czechia

Centre Hospitalier Universitaire (CHU) de Bordeaux - Hôpital Pellegrin

Bordeaux, France

Centre Hospitalier Universitaire (CHU) de Grenoble Alpes - Hôpital Michallon

La Tronche, France

Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital de Rangueil

Toulouse, France

Charité - Universitätsmedizin Berlin

Berlin, Germany

Universitaetsklinikum Carl Gustav Carus Dresden

Dresden, Germany

Universitätsklinikum Hamburg-Eppendorf

Hamburg, Germany

Hospital Del Mar

Barcelona, Spain

Hospital Universitario Vall d'Hebron

Barcelona, Spain

Hospital Universitario de Bellvitge

Barcelona, Spain

Hospital Universitario Miguel Servet

Zaragoza, Spain